Literature DB >> 31531786

Clinical impact of segmental renal vein invasion on recurrence in patients with clinical T1 renal cell carcinoma undergoing partial nephrectomy.

Takashi Yoshida1, Chisato Ohe2, Toyonori Tsuzuki3, Motohiko Sugi1, Hidefumi Kinoshita1, Koji Tsuta4, Tadashi Matsuda1.   

Abstract

BACKGROUND: This study evaluated the clinical significance of pathological factors associated with T3a upstaging according to the American Joint Committee on Cancer/Union for International Cancer Control 8th edition TNM-staging system in patients with clinical T1 renal cell carcinoma undergoing definitive surgery.
METHODS: We retrospectively investigated 418 patients with renal cell carcinoma who underwent partial or radical nephrectomy at our institution between 2006 and 2016. Surgical specimens were grossly and microscopically re-reviewed with respect to extrarenal extension patterns by two urological pathologists. Kaplan-Meier analysis and Cox regression were used to determine the impact of the factors associated with pathological stage T3a on recurrence-free survival. Harrell's c-index was used to compare the prognostic accuracy of the current and previous staging systems.
RESULTS: Overall, the 5-year recurrence-free survival was 94.5% (median follow-up duration, 60.8 months). Of 418 patients, 46 (11.0%) were upstaged to pathological stage T3a, including 12/267 (4.5%) and 34/151 (22.5%) in the partial and radical nephrectomy groups, respectively. Among these upstaged patients, partial nephrectomy was significantly associated with a higher recurrence rate than radical nephrectomy (5-year recurrence-free survival: 48.9 vs. 83.9%, P = 0.0172). Although perinephric fat invasion had the highest c-index in all patients (0.580-0.679), microscopic segmental renal vein invasion was a significant predictor of recurrence in patients undergoing partial nephrectomy (c-index, 0.60).
CONCLUSION: Assessing microscopic segmental renal vein invasion, which has been included in the current staging system recently, is essential to accurately predict the oncological outcome in the era of partial nephrectomy for clinical T1 renal cell carcinoma.

Entities:  

Keywords:  Nephrectomy; Recurrence; Renal cell carcinoma; TNM staging; Upstaging

Mesh:

Year:  2019        PMID: 31531786     DOI: 10.1007/s10147-019-01543-6

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  18 in total

1.  Significance of Pathologic T3a Upstaging in Clinical T1 Renal Masses Undergoing Nephrectomy.

Authors:  Krishna Ramaswamy; Emil Kheterpal; Hai Pham; Sanjay Mohan; Michael Stifelman; Samir Taneja; William C Huang
Journal:  Clin Genitourin Cancer       Date:  2015-01-22       Impact factor: 2.872

Review 2.  Partial nephrectomy versus radical nephrectomy for clinical localised renal masses.

Authors:  Frank Kunath; Stefanie Schmidt; Laura-Maria Krabbe; Arkadiusz Miernik; Philipp Dahm; Anne Cleves; Mario Walther; Nils Kroeger
Journal:  Cochrane Database Syst Rev       Date:  2017-05-09

3.  Challenges in Pathologic Staging of Renal Cell Carcinoma: A Study of Interobserver Variability Among Urologic Pathologists.

Authors:  Sean R Williamson; Priya Rao; Ondrej Hes; Jonathan I Epstein; Steven C Smith; Maria M Picken; Ming Zhou; Maria S Tretiakova; Satish K Tickoo; Ying-Bei Chen; Victor E Reuter; Stewart Fleming; Fiona M Maclean; Nilesh S Gupta; Naoto Kuroda; Brett Delahunt; Rohit Mehra; Christopher G Przybycin; Liang Cheng; John N Eble; David J Grignon; Holger Moch; Jose I Lopez; Lakshmi P Kunju; Pheroze Tamboli; John R Srigley; Mahul B Amin; Guido Martignoni; Michelle S Hirsch; Stephen M Bonsib; Kiril Trpkov
Journal:  Am J Surg Pathol       Date:  2018-09       Impact factor: 6.394

4.  Nephrometry score correlated with tumor proliferative activity inT1 clear cell renal cell carcinoma.

Authors:  Hiroshi Kikuchi; Takashige Abe; Ryuji Matsumoto; Takahiro Osawa; Satoru Maruyama; Sachiyo Murai; Nobuo Shinohara
Journal:  Urol Oncol       Date:  2019-02-27       Impact factor: 3.498

5.  Prognostic evaluation of perinephric fat, renal sinus fat, and renal vein invasion for patients with pathological stage T3a clear-cell renal cell carcinoma.

Authors:  Paras H Shah; Timothy D Lyon; Christine M Lohse; John C Cheville; Bradley C Leibovich; Stephen A Boorjian; R Houston Thompson
Journal:  BJU Int       Date:  2018-09-09       Impact factor: 5.588

6.  The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth.

Authors:  Alexander Kutikov; Robert G Uzzo
Journal:  J Urol       Date:  2009-07-17       Impact factor: 7.450

7.  Investigation of the freely available easy-to-use software 'EZR' for medical statistics.

Authors:  Y Kanda
Journal:  Bone Marrow Transplant       Date:  2012-12-03       Impact factor: 5.483

8.  Outcomes and predictors of clinical T1 to pathological T3a tumor up-staging after robotic partial nephrectomy: a multi-institutional analysis.

Authors:  Michael A Gorin; Mark W Ball; Phillip M Pierorazio; Youssef S Tanagho; Sam B Bhayani; Jihad H Kaouk; Craig G Rogers; Michael D Stifelman; Ali Khalifeh; Ramesh Kumar; Ganesh Sivarajan; Mohamad E Allaf
Journal:  J Urol       Date:  2013-06-11       Impact factor: 7.450

9.  Pathological Upstaging of Clinical T1 to Pathological T3a Renal Cell Carcinoma: A Multi-institutional Analysis of Short-term Outcomes.

Authors:  Jasmir G Nayak; Premal Patel; Olli Saarela; Zhihui Liu; Anil Kapoor; Antonio Finelli; Simon Tanguay; Ricardo Rendon; Ron Moore; Peter C Black; Louis Lacombe; Rodney H Breau; Jun Kawakami; Darrel E Drachenberg
Journal:  Urology       Date:  2016-03-31       Impact factor: 2.649

10.  Outcomes of pathologic stage T3a renal cell carcinoma up-staged from small renal tumor: emphasis on partial nephrectomy.

Authors:  Hakmin Lee; Minseung Lee; Sang Eun Lee; Seok-Soo Byun; Hyeon Hoe Kim; Cheol Kwak; Sung Kyu Hong
Journal:  BMC Cancer       Date:  2018-04-16       Impact factor: 4.430

View more
  4 in total

1.  The SSPN Score, a Novel Scoring System Incorporating PBRM1 Expression, Predicts Postoperative Recurrence for Patients with Non-metastatic Clear Cell Renal Cell Carcinoma.

Authors:  Haruyuki Ohsugi; Takashi Yoshida; Chisato Ohe; Junichi Ikeda; Motohiko Sugi; Hidefumi Kinoshita; Koji Tsuta; Tadashi Matsuda
Journal:  Ann Surg Oncol       Date:  2020-09-17       Impact factor: 5.344

2.  Development and validation of a vascularity-based architectural classification for clear cell renal cell carcinoma: correlation with conventional pathological prognostic factors, gene expression patterns, and clinical outcomes.

Authors:  Chisato Ohe; Takashi Yoshida; Mahul B Amin; Naho Atsumi; Junichi Ikeda; Kazuho Saiga; Yuri Noda; Yoshiki Yasukochi; Riuko Ohashi; Haruyuki Ohsugi; Koichiro Higasa; Hidefumi Kinoshita; Koji Tsuta
Journal:  Mod Pathol       Date:  2021-11-30       Impact factor: 7.842

3.  A novel nomogram can predict pathological T3a upstaged from clinical T1a in localized renal cell carcinoma.

Authors:  Chuanzhen Cao; Xiangpeng Kang; Bingqing Shang; Jianzhong Shou; Hongzhe Shi; Weixing Jiang; Ruiyang Xie; Jin Zhang; Lianyu Zhang; Shan Zheng; Xingang Bi; Changling Li; Jianhui Ma
Journal:  Int Braz J Urol       Date:  2022 Sep-Oct       Impact factor: 3.050

4.  Integration of NRP1, RGS5, and FOXM1 expression, and tumour necrosis, as a postoperative prognostic classifier based on molecular subtypes of clear cell renal cell carcinoma.

Authors:  Takashi Yoshida; Chisato Ohe; Junichi Ikeda; Naho Atsumi; Ryoichi Saito; Hisanori Taniguchi; Haruyuki Ohsugi; Motohiko Sugi; Koji Tsuta; Tadashi Matsuda; Hidefumi Kinoshita
Journal:  J Pathol Clin Res       Date:  2021-07-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.